Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Rutgers AIDS researchers progress toward vaccine

Rutgers AIDS researchers Gail Ferstandig Arnold and Eddy Arnold may have turned a corner in their search for a HIV vaccine.

12 Mar 2009

Biothera receives approval to launch two lung cancer trials

German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGGÂ® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.

12 Mar 2009

A blood test for Alzheimer's on the horizon

Researchers have revealed a direct relationship between two specific antibodies and the severity of Alzheimer's disease symptoms, raising hopes that a diagnostic blood test for the devastating disorder is within reach.

11 Mar 2009

Study of Rituxan (rituximab) in lupus nephritis misses primary endpoint

Genentech, Inc. and Biogen Idec has announced that a Phase III study of Rituxan (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks.

11 Mar 2009

Twin nanoparticle targets then zaps breast cancer cells

Breast cancer patients face many horrors, including those that arise when fighting the cancer itself.

11 Mar 2009

Tissue-cultured smallpox vaccine shows promise

Administration of a tissue-cultured smallpox vaccine showed signs of an effective vaccine response with no serious adverse events, according to a study in the March 11 issue of JAMA, the Journal of the American Medical Association.

11 Mar 2009

Rituximab useful for advanced indolent lymphoma

A new study has found for the first time that maintenance therapy with the novel antibody, rituximab (MR) following cyclophosphamide, vincristine and prednisone (CVP) therapy improves progression-free survival in patients with stage III-IV indolent lymphoma, according to Howard S. Hochster, M.D. of NYU Langone Medical Center, lead author of a recent study published online ahead of print in the Journal of Clinical Oncology.

11 Mar 2009

New staging technique might save bladders in some bladder cancer patients

Pathologists have reported encouraging results from a new technique to increase the accuracy of staging bladder cancer tumors that could reduce the need to remove bladders from some patients.

10 Mar 2009

CytoDyn responds to FDA as high court rules agency cannot guarantee drug safety

CytoDyn, Inc. has sent the FDA what the Company believes is a complete response to the agency's preliminary comments on Cytolin, a monoclonal antibody designed to restore immune function in those afflicted with HIV/AIDS.

10 Mar 2009

Number of cardiovascular risk factors could determine safety of IVIg treatment

New research out of Wake Forest University School of Medicine identifies the presence of cardiovascular risk factors as an indicator of how likely it is that elderly, hospitalized patients who receive intravenous immunoglobulin (IVIg) treatment will have a stroke or heart attack.

5 Mar 2009

Patented inventions double at University at Buffalo

An antibody with the potential to stop breast cancer in its path. A nanoparticle that can address a side effect of the treatment that hemophiliacs cannot live without. A "quantum dot" with the potential to treat cancer or harvest the power of the sun. An air purifier that kills the world's nastiest toxins.

5 Mar 2009

Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment

5 Mar 2009

Rituximab reduces kidney inflammation in patients with severe lupus nephritis

Treatment with the targeted drug rituximab can significantly benefit some patients with severe lupus nephritis who do not respond to conventional therapy, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

4 Mar 2009

Patients with severe asthma benefit from injections of the antibody, mepolizumab

McMaster University researchers have found patients with a very severe asthma benefit from injections of the antibody, mepolizumab.

4 Mar 2009

Antibody key to treating variant CJD

Scientists at the University of Liverpool have determined the atomic structure of the 'binding' between a brain protein and an antibody that could be key to treating patients with diseases such as variant CJD.

4 Mar 2009

Axela introduces dotLab Amine Reactive Sensor

Axela Inc has introduced the dotLab Amine Reactive Sensor for stable covalent coupling of affinity reagents such as antibodies for use with the Axela dotLab System.

4 Mar 2009

Better understanding of immune system activation

Linda Andersson at Malmo University in Sweden has studied the ability of dendritic cells to sample the surrounding environment. To understand how different materials are taken up and what happens within the cells can for example facilitate the development of new vaccines.

3 Mar 2009

Instant immunity through chemically programmable vaccination and covalent self-assembly

The experiments, thus far performed only in mice, appear to overcome a major drawback of vaccinations - the lag time of days, or even weeks, that it normally takes for immunity to build against a pathogen.

2 Mar 2009

Epstein-Barr virus may be associated with progression of multiple sclerosis

Epstein-Barr virus (EBV), the pathogen that causes mononucleosis, appears to play a role in the neurodegeneration that occurs in persons with multiple sclerosis, researchers at the University at Buffalo and the University of Trieste, Italy, have shown.

2 Mar 2009

The obesity paradox

It's called the obesity paradox. Although obese people are more apt to suffer from inflammatory diseases, such as diabetes, heart disease, and stroke, they are also more likely to survive a major attack caused by one of those conditions.

26 Feb 2009